Connect with us

Market

Latest Developments: Netlist, Inc. (NASDAQ:NLST), Federal Home Loan Mortgage Corp (OTCBB:FMCC), Cannabis Science, Inc. (OTCMKTS:CBIS)

Published

on

Federal Home Loan Mortgage Corp (OTCBB:FMCC) shares is trading at $3.17. The company on Jan. 16 announced that it auctioned a $1 billion reopening of its 1.75% seven-year USD Reference Notes® security that matures on May 30, 2019. The stop yield for the issue, CUSIP 3137EADG1, was 1.947%, priced at 98.999425. The bid-to-cover ratio was 3.4 to 1. After the reopening, which was conducted via an Internet-based auction, the outstanding size of the 1.75% seven-year Reference Notes security will be $4 billion.

Free Urgent Insider Catalyst Report For FMCC Available Here

Additionally, the company on Jan. 6 announced a new offering of Structured Pass-Through Certificates (“K Certificates”) backed exclusively by fixed-rate multifamily mortgages with a 7-year term. The company expects to offer approximately $1 billion in K Certificates (“K-714 Certificates”), which are expected to price the week of Jan. 6, 2014, and settle on or about Jan. 28, 2014. This is Freddie Mac’s first K Certificate offering this year.

Cannabis Science, Inc. (OTCMKTS:CBIS) shares is trading at $0.083. The company on Jan. 16 announces plans for international observational studies and research in 2014. Cannabis Science is a cannabinoid portfolio company.  Plans announced by Cannabis Science to launch an observational clinical research study in 2014 will focus on patient driven use of cannabis and cannabis based products and the clinical outcomes of such use for a variety of medical conditions.  Cannabis Science will seek additional funding partners as well as academic and clinical collaborators for this project.

Free Urgent Insider Catalyst Report For CBIS Available Here

CBIS has been continuously conducting research into on cannabis and cannabinoids and in 2013 has also filed an application of a cannabinoid based patent and believes there is an enormous potential for the extension of its portfolio and filing of further patents.

Netlist, Inc. (NASDAQ:NLST) shares increased 15.38% to $1.52. The company on Jan. 17  announced today that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office issued a decision upholding the validity of all 60 claims in the reexamination of U.S. Pat. No. 7,532,537 (“‘537 Patent”) brought by Inphi Corporation. In its decision on January 16, 2014, the PTAB dismissed every single validity challenge raised by Inphi and affirmed the Examiner’s decision to allow the claims

Free Urgent Insider Catalyst Report For NLST Available Here 

Additionally, the company on Jan. 16 announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for two of Netlist’s pending patent applications covering core aspects of hybrid memory systems that combine DRAM and FLASH memory technologies. Hybrid memory systems combine the speed, endurance, and reliability of DRAM with the persistence, high density and low cost of FLASH.

Biotech

CytoDyn Inc (OTCMKTS:CYDY) Regains Momentum After The Big Announcement

Published

on

By

Now that the market seems to be coming back into his elements, it could be time for investors to start looking into penny stocks more closely. These stocks may often be risky, but if one makes the right choice, then the rewards could be enormous. One penny stock that could be put into the watch list at this point in time is that of CytoDyn Inc (OTCMKTS:CYDY).

The late-stage biotechnology company, which is developing the coronavirus medicine leronlimab, announced last week that it had filed a comprehensive application for uplisting on NASDAQ. The company announced that it believes that its application satisfies the myriad listing requirements of the NASDAQ Capital Market.

The Chief Executive Officer and President of the company Nader Pourhassan stated that while it is true that the entire process is expected to take many weeks, CytoDyn is hopeful of success in this matter.

He went on to state that a listing on NASDAQ will not only provide shareholders with more liquidity but also give CytoDyn much bigger access to fresh capital. It is a significant development for the company, and the market participants realized it as well. After the announcement was made, the stock rallied by as much as 50%. Investors could do well to keep an eye on the stock this week.

While the rally following this announcement was a welcome relief for the company, it is important to point out that earlier on in the week, the stock has fallen considerably following a setback. Last Monday, the company announced that the United States Food and Drug Administration handed CytoDyn a refusal to file a letter with regards to the usage of leronlimab to treat HIV.

However, at the same time, investors should be noted that the company did announce that it is confident of furnishing the agency with all the further details that have been demanded. It is one of the penny stocks that have performed remarkably well this year so far, and investors could keep an eye on it.

Continue Reading

Market

These 3 Pot Stocks Are Up Big Since May: What’s the Buzz?

Published

on

By

Over the course of the past year or so, pot stocks had generally struggled, but during the past month, those stocks have recovered nicely. The stock market suffered a historic fall due to the economic turmoil caused by the coronavirus pandemic. It is believed that investors who are looking for value have descended on the beaten-down pot stocks. On the flip side, these stocks could also have been identified as defensive plays in an uncertain market environment.

That being said, it should be noted that despite the gains recorded by many stocks, most of those stocks are still considerably lower than the all-time highs. In such a situation, it could be worthwhile for investors to take a closer look at some of the strongest and more stable cannabis companies in the industry. Here is a look at three pot stocks that made significant moves in May and could be tracked by investors at this point.

1. HEXO Stock Jumps Ahead of Earnings

HEXO Corp (TSX:HEXO) (NYSE:HEXO) is one of those cannabis companies which have had a particularly tough time over the past year or so. However, the stock has emerged as one of the bigger gainers among pot stocks in recent trading sessions. The Hexo stock has gained as much as 120% over the course of the past month. The company is all set to release its financial results for the fiscal third quarter on Thursday, and hence, it could be a big week for the stock.

The recent surge in the Hexo stock may have come as a major boost to investors, but it should be noted that over the past year, it recorded considerable losses. The beaten-down nature of the stock may have contributed to the stock becoming more attractive for investors. However, the trajectory of the Hexo stock in the near term is going to depend a lot on its third-quarter earnings.

The company had made a loss of $298 million in the previous quarter, and while it is almost certain that it is going to make a loss again, the size of the loss is going to be keenly watched. Additionally, any writedowns are also going to be harmful to the stock. Investors should also keep an eye on sales growth.

2 Organigram gains Momentum on Value Buying

Organigram Holdings (TSX:OGI) (NASDAQ:OGI) is another pot stock that has made significant gains in the past month. Since May 13, the stock has gained as much as 80%. In April, the company announced its fiscal second-quarter results, but it had been a disappointment.

Revenues dropped by 13.7% year on year to hit CA$23.2 million, and losses widened to CA$6.8 million from CA$6.4 million in the prior-year period. However, one significant cause for optimism for Organigram investors is the fact that in the second quarter, cannabis 2.0 products made up as much as 13% of its revenue. That has opened up a whole new opportunity for the company.

Wholesale cannabis revenue made up 24% of the net, and that is again a new source of revenue. The company blamed the lower volumes of flower as well as cannabis oil for the drop in sales. Organigram reported cash and cash equivalents of CA$41.1 million as of February 29. Considering the fact that it has burned CA$25 million in the past six months, investors should not use that the cash balance does not paint a pretty picture.

3 Aphria Recovers Following Solid Earnings

Aphria (TSX:APHA) (NYSE:APHA), on the other hand, managed to perform relatively well in its fiscal third quarter. The net sales rose by as much as 19.7% sequentially to hit CA$144.4 million, and more importantly, the company also managed to record a profit for the third time in four quarters. On top of that, it should be noted that although the Canadian cannabis company spends CA$124.4 million on its operations in the nine months trailing that quarter, it still reported a cash balance of CA$515 million.

The performance seems to have buoyed market participants as well, and the stock has rallied by as much as 75% since the middle of May. One of the most important things that investors are going to be looking into is whether Aphria is going to be able to maintain its profitability.

However, due to the turmoil caused by the coronavirus pandemic, it might prove difficult. That being said, it should be noted that the pandemic is going to have an equally damaging effect across the sector.

Continue Reading

Market

ConforMIS Inc (NASDAQ: CFMS): Premium Members Made A Quick 65% Profit In Just 1 week

Published

on

Well, as we know there are two types of person in the stock market one is trader and another is investor. Investors tend to put money for longer time, while traders make short term bets. We know, its not at all easy to make money in the short term especially in the equity markets. However, premium members at Traders Insights are making awesome money on our calls on our swing trading calls. WE ARE OFFERING A SPECIAL 7-Day Trial Period at Just $5 (so that everybody can make money with us and join us if satisfied). Register Here http://tradersinsights.com/pricing/
JOIN US NOW: For Details Contact us at info@tradersinsights.com

Or You can send me a friend request on facebook here https://www.facebook.com/sebastian.gomestradersinsights

Now let me show you how we made quick 43% in just 1-week which was posted to our premium members:-

We told our members in facebook private group to buy ConforMIS Inc (NASDAQ: CFMS) yesterday (march 13th) at $1.36. Now look at the price of the stock – its up 65% at $2.25 from our buy price. This is how easy money they made. If you had invested $5,000 in CFMS, it could had been moved up to $8,250. It’s not yet late, join us at info@tradersinsights.com

Continue Reading
Advertisement

Trending